Shardul Amarchand Mangaldas & Co advises Book Running Lead Managers on ₹ 1,200 crores QIP of Max Healthcare Institute Limited
March 12, 2021
Shardul Amarchand Mangaldas & Co advised Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Credit Suisse Securities (India) Private Limited, HSBC Securities and Capital Markets (India) Private Limited (Book Running Lead Managers) on the ₹ 1,200 crores qualified institutional placement (QIP) of Max Healthcare Institute Limited. The date of closing was 10 March 2021.
Max Healthcare Institute Limited is India’s second largest private healthcare network by revenue, and has a network of 16 Network Healthcare Facilities.
This will be the third healthcare transaction in 2021 for the capital markets team following the Apollo Hospitals QIP (in January 2021) and the initial public offer of Krishna Institute of Medical Sciences Limited (DRHP filed in February 2021).
The transaction team was led by Prashant Gupta, National Practice Head and Monal Mukherjee, Partner; assisted by Anjali Verghese, Senior Associate; Maharghya Biswas, Associate; Sanjana Chowdhry, Associate; and Rudresh Mandal, Associate.
AZB & Partners advised Max Healthcare Institute Limited. Linklaters Singapore Pte. Ltd. advised the Book Running Lead Managers as to United States law.
The Bar Council of India does not permit solicitation of work and advertising by legal practitioners and advocates. By accessing the Shardul Amarchand Mangaldas & Co. website (our website), the user acknowledges that:
The user wishes to gain more information about us for his/her information and use. He/She also acknowledges that there has been no attempt by us to advertise or solicit work.
Any information obtained or downloaded by the user from our website does not lead to the creation of the client – attorney relationship between the Firm and the user.
None of the information contained in our website amounts to any form of legal opinion or legal advice.
All information contained in our website is the intellectual property of the Firm.